Abstract
The γ-aminobutyric acidA (GABAA) receptor contains a binding site (or sites) for benzodiazepines and related ligands. Previous studies have shown that the residue occupying position 101 (rat numbering) of the α subunit is particularly important in determining how some of these compounds interact with the receptor. We have made multiple substitutions (F, Y, K, Q, and E) of the histidine at this position of the rat α1 subunit and coexpressed the mutant subunits with β2 and γ2 subunits inXenopus oocytes. The effects of flunitrazepam, Ro15-1788, and Ro15-4513 on GABA-gated currents were then examined using electrophysiological techniques. Three substitutions (F, Y, and Q) had little effect on the ability of flunitrazepam to potentiate GABA-induced currents and had relatively modest effects on the EC50 value of the flunitrazepam response. Other mutations (K and E) resulted in drastic reduction of flunitrazepam recognition. All substitutions also affected the EC50 values for Ro15-1788 and Ro15-4513, and some led to dramatic changes in their efficacy. For example, H101Y, H101K, and H101Q produced receptors at which Ro15-1788 acted as a partial agonist (maximum potentiation of 164, 159, and 130%, respectively), whereas Ro15-4513 acted as a partial agonist at H101F, H101K, and H101E (potentiation of 122, 138, and 110%, respectively) and an antagonist at H101Y and H101Q. These results indicate that the characteristics of the residue at position 101 of the α1 subunit play a crucial role in determining the efficacy of benzodiazepine-site ligands.
Footnotes
-
Send reprint requests to: Dr. Susan M. J. Dunn, Department of Pharmacology, 9-70 Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada T6G 2H7. E-mail:Susan.Dunn{at}UAlberta.CA
-
This work was supported by the Medical Research Council of Canada (S.M.J.D.), the Savoy Foundation (M.D., S.M.J.D.) and the Medical Research Council of the United Kingdom (J.J.L.).
- Abbreviations:
- GABA
- γ-aminobutyric acid
- GABAA
- γ-aminobutyric acid type A, FNZ, flunitrazepam
- Received February 9, 1999.
- Accepted July 16, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|